Company About Elekta Contact Us Board of Directors Executive Management Patient Information Radiation Therapy Treatment Gamma Knife Treatment Brachytherapy Treatment Treatment Centers Media Resources Press Releases Social Media Events & Tradeshows Wavelength Magazine Company Information Code of Conduct Legal Notices Regulatory Affairs Programs Corporate Giving Careers Asia Products & Solutions Radiotherapy Stereotactic Radiosurgery Oncology Informatics Brachytherapy Neurosurgery Particle Therapy Treatment Delivery Versa HD Infinity Synergy Precise Compact Treatment Solutions Advanced Imaging Motion Management QA Solutions Beam Shaping Patient Positioning Oncology Informatics MOSAIQ Treatment Planning Monaco Versa HD with HDRS Treatment Delivery Leksell Gamma Knife Icon Leksell Gamma Knife Perfexion Versa HD Treatment Planning Leksell GammaPlan Monaco Registry LGK Registry Leksell Gamma Knife Icon MOSAIQ Oncology Specific EMR Radiation Oncology Medical Oncology Workflow Automation Patient Engagement MOSAIQ Oncology Analytics Clinical Performance Operational Performance Financial Performance MOSAIQ Image and Plan Review Plan Evaluation Stereotactic Localization Registry METRIQ MOSAIQ Oncology Analytics Treatment Delivery Flexitron microSelectron Esteya Real-time Prostate Treatment Planning Oncentra Brachy Applicators Bronchus / Esophagus Breast Gynecological Prostate Rectum / Bladder Venezia Leksell Vantage Stereotactic System Neuromag TRIUX Leksell Stereotactic System Services Service & Support Contact Support SupportPlus Portal Elekta Care Education & Training Get Help Contact Support Investors Elekta in brief Corporate Governance The Share Financials Reports Presentations Press Releases IR Calendar Subscriptions IR Contact Value Creation Solutions About Cancer About Radiation Therapy Production Glossary Annual General Meeting Extraordinary General Meeting Board of Directors Executive Management Nomination Committee Compensation Committee Audit Committee Reporting and Audit Remuneration to executive management Code of conduct Articles of Association Corporate Governance Report Convertible Debentures Total Return Share Price Calculator Largest Shareholders Distribution of Shareholding Repurchase of Elekta Shares Insiders Insider Transactions Share Capital and Number of Shares Elekta Share in Brief Analysts Market Estimates Dividend Policy Data per Share Definitions Financial Ambitions MTN - Program Annual Reports Interim Reports JOHAN ANDERSSON Director and Head of Investor Relations Phone - Direct: +46 8 587 254 15 johan.andersson@elekta.com TOBIAS BÜLOW Director Financial Communications Phone - Direct: +46 8 587 257 34 tobias.bulow@elekta.com FRIDA JOHANSSON Investor Relations Phone - Direct: +46 70 866 76 74 frida.johansson@elekta.com Future Tech Future Technologies As pioneers of future technology, Elekta is setting a new standard of cancer care once again with magnetic resonance radiation therapy (MR/RT). MR/RT addresses an unmet need in cancer therapy, enabling clinicians to confidently see and track difficult to visualize soft-tissue anatomies. Company About Elekta Contact Us Board of Directors Executive Managment Media Resources Press Releases Social Media Events & Tradeshows Wavelength Magazine Company Information Code of Conduct Legal Notices Regulatory Affairs Programs Corporate Giving Patient Information Radiation Therapy Treatment Gamma Knife Treatment Brachytherapy Treatment Treatment Centers Careers Products & Solutions Radiotherapy Treatment Delivery Versa HD Infinity Synergy Precise Compact Treatment Solutions Advanced Imaging Motion Management QA Solutions Beam Shaping Patient Positioning Oncology Informatics MOSAIQ Treatment Planning Monaco Stereotactic Radiosurgery Treatment Delivery Leksell Gamma Knife Icon Leksell Gamma Knife Perfexion Versa HD Treatment Planning Leksell GammaPlan Monaco Registry LGK Registry Oncology Informatics MOSAIQ Oncology Specific EMR Radiation Oncology Medical Oncology Workflow Automation Patient Engagement MOSAIQ Oncology Analytics Clinical Performance Operational Performance Financial Performance MOSAIQ Image and Plan Review Plan Evaluation Stereotactic Localization Registry METRIQ Brachytherapy Treatment Delivery Flexitron microSelectron Esteya Real-time Prostate Treatment Planning Oncentra Brachy Applicators Bronchus / Esophagus Breast Gynecological Prostate Rectum / Bladder Neurosurgery Leksell Vantage Stereotactic System Neuromag TRIUX Leksell Stereotactic System Particle Therapy Services Contact Elekta Care Support SupportPlus Portal Education & Training Investors Elekta in Brief Value Creation Solutions About Cancer About Radiation Therapy Production Glossary Corporate Governance Annual General Meeting Extraordinary General Meeting Board of Directors Executive Management Nomination Committee Compensation Committee Audit Committee Reporting and Audit Remuneration to executive management Code of conduct Articles of Association Corporate Governance Report The Share Total Return Share Price Calculator Largest Shareholders Distribution of Shareholding Insiders Insider Transactions Share Capital and Number of Shares Elekta Share in Brief Analysts Market Estimates Dividend Policy Data per Share Convertible Debentures Repurchase of Elekta Shares Financials Definitions Financial Ambitions MTN - Program Reports Annual Reports Interim Reports Presentations Press Releases IR Calendar Subscriptions IR Contact Future Technologies Global Websites Contact Us SupportPlus Audit Committee Swedish The Audit Committee is appointed by Elekta’s Board of Directors and monitors the quality of the financial reporting, risk management, the correct use of established financial principles, examines the work of the auditors and informs the Board. Composition The Audit Committee consists of three members, appointed by the Board at the first Board meeting following the election of the Board by the Annual General Meeting of Shareholders for a term of one year. The members of the Committee are Birgitta Stymne Göransson, who is also the Chairman of the Committee, Jan Secher and Annika Espander Jansson. The President and CEO, the CFO and the Chief Audit Executive also attend the Committee’s meetings as well as the external auditor as applicable. The General Counsel serves as secretary for the Committee. Responsibility The objective of the Audit Committee is to monitor the Group’s financial reporting and the effectiveness of the Group’s internal control, internal audit and risk management. The objective is also to keep itself informed about the external audit of the annual report and consolidated report of Elekta AB as well as to review and monitor the impartiality and independence of the external auditor, and pay particular attention if the external auditor provides the Group with services other than audit services. Furthermore, the objective is to assist the Nomination Committee in preparing the proposal to the Annual General Meeting of Shareholders regarding election of external auditor. The Committee works in accordance with Working Instructions for the Audit Committee adopted by the Board. The Committee keeps the Board regularly informed and prepares matters to the Board for decision. Refer to Elekta’s Corporate Governance Report for more information about the Committee’s work, meeting attendance, etc. during 2016/17. Elekta in brief Value Creation Solutions About Cancer About Radiation Therapy Production Glossary Corporate Governance Annual General Meeting Extraordinary General Meeting Board of Directors Executive Management Nomination Committee Compensation Committee Audit Committee Reporting and Audit Remuneration to executive management Code of conduct Articles of Association Corporate Governance Report The Share Total Return Share Price Calculator Largest Shareholders Distribution of Shareholding Insiders Insider Transactions Share Capital and Number of Shares Elekta Share in Brief Analysts Market Estimates Dividend Policy Data per Share Convertible Debentures Repurchase of Elekta Shares Financials Definitions Financial Ambitions MTN - Program Reports Annual Reports Interim Reports Presentations Press Releases IR Calendar Subscriptions IR Contact Subscribe Contact Investor Relations Johan Andersson Director and Head of Investor Relations +46 8 587 254 15 johan.andersson@elekta.com Tobias Bülow Director Financial Communications +46 8 587 257 34 tobias.bulow@elekta.com Discover Radiotherapy Stereotactic Radiosurgery Oncology Informatics Neurosurgery Brachytherapy Particle Therapy Connect Social Media Browse Elekta Events Download Magazine Find Us Office Locations Industry Recognition Media Resources Product Photos Explore User Meetings & Events Education & Training Elekta Care Careers at Elekta Focus where it matters. © 2017 Elekta AB (pub) | Legal Notices | Privacy Policy Important Safety Information: Radiation therapy is not appropriate for all patients. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. In some patients, they can be severe. Treatment sessions may vary in complexity and time. Refer to individual product labeling (instructions for use) for more complete information on product safety and effectiveness for its intended use.